- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
June 7, 2023Partner Tim Billion Honored With 2023 Appellate Advocacy Award
June 6, 2023Super Lawyers Names Five Attorneys to “Southern California Rising Stars” List
June 1, 2023Chambers USA Recognizes Five Robins Kaplan Practice Groups and 17 Lawyers in 2023 Guide
June 13, 20232023 Probate and Trust Law Section Conference
June 14, 2023Leading Through Uncertainty
June 15, 2023Enhance Your Super Powers by Clerking
May 2023Raoul Shah: Keeping Humanity and Compassion Close
May 18, 2023NFT Trademark Defense Comes Down To Licensing Terms
April 20, 2023Drafting Subsequent Agreements to Avoid Arbitrability Litigation
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Consumer Alert: Lariam Antimalarial Drug and Permanent Neuropsychological Side Effects
August 19, 2013
Attorneys at Robins, Kaplan, Miller & Ciresi are investigating reports of serious neurological and psychiatric side effects associated with mefloquine hydrochloride—a drug used in the prevention and treatment of malaria. Reports have linked the drug to thousands of adverse reports of psychiatric problems, including suicide, attempted suicide, aggression towards others, psychosis, paranoia, hallucinations, anxiety, panic, dizziness, loss of balance, and depression.
On July 29, 2013, the U.S. Food and Drug Administration (FDA) issued a safety alert to doctors and the public regarding updated warnings of long lasting neuropsychiatric side effects associated with mefloquine. The FDA noted that some of these side effects may persist or become permanent. Mefloquine now has a Black Box Warning on its label—most serious kind of warning about potential side effects.
Mefloquine is commonly used by international travelers, including vacationers, military service members, Peace Corps Volunteers, and business travelers. Mefloquine has been a popular antimalarial drug, particularly because consumers need only take the drug once a week rather than daily. Yet, alternative antimalarial medications not associated with permanent neuropsychological side effects exist on the market.
Mefloquine was originally developed by the United States Army and entered the commercial market in 1989. It has also been referred to as Lariam, Mephaquin, or Mefliam. There have been four manufacturers of Mefloquine in the United States market:
- Hoffman La Roche (brand name Lariam)
- Boehringer Ingelheim, Roxane Laboratories (generic version)
- Sandoz Inc. (generic version)
- Teva Pharmaceuticals (generic version)
If you have taken Mefloquine or Lariam and have experienced Mefloquine side effects, please contact the law firm of Robins, Kaplan, Miller & Ciresi for a free consultation. We have attorneys and legal nurse consultants on staff ready to assist you. All calls are kept confidential. You may be entitled to compensation.
© 2013 Robins, Kaplan, Miller & Ciresi L.L.P.
The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.